Breakthrough in HIV/AIDS Treatment: Researchers Discover New Combination Therapy

Strategic Insights -

Researchers at the University of Campania 'Luigi Vanvitelli' in Naples, Italy, have made a significant breakthrough in HIV/AIDS treatment by exploring new combination therapies. Despite the progress of antiretroviral therapy, some patients with multidrug-resistant (MDR) HIV infection continue to struggle with the disease. The study investigated the use of new-generation drugs, such as Ibalizumab (IBA) and Lenacapavir (LEN), in combination with an optimized background regimen.

Key Takeaways:

  • The researchers found that IBA was efficacious in the rescue regimen, achieving viral suppression in just one month, with a significant improvement in the CD4+ count and a progressive disappearance of viral mutations in the reservoir.
  • The study also found that LEN, administered subcutaneously every 6 months, preserved efficacy and stable pressure on HIV-DNA, while being well-tolerated with only one side effect - the onset of hypertension after infusions.
  • The study suggests that switching from IBA to LEN can be an effective strategy for treating HTE patients with MDR HIV-1 infection.
  • The study's case report provides valuable insights into the use of new-generation drugs for HIV treatment, highlighting the importance of optimizing adherence and switching strategies for effective patient outcomes.
  • The research was conducted by a team of researchers led by Salvatore Martini, with additional authors including Lorenzo Salmoni, Roberta Palladino, Antonio Russo, Mario Starace, Carmine Minichini, Mariantonietta Pisaturo, Nicola Coppola, Nunzia Cuomo, and Adriana Raddi.

Statistics:

  • The patient in the study had a viral load of 37,800 copies/mL and a CD4+ count of 147 cells/μL at the start of treatment.
  • IBA was administered intravenously every 15 days, while LEN was given subcutaneously every 6 months.
  • After 12 months, the patient's viral load was undetectable, and the CD4+ count had increased significantly.
  • The study's results suggest that the switch from IBA to LEN preserved efficacy and stable pressure on HIV-DNA, with only one side effect reported.

Sources:

  • Switch From Ibalizumab To Lenacapavir In a Rescue Regimen for a Heavily Treatment-experienced (Hte) Patient With Multidrug-resistant (Mdr) Hiv-1 Infection. International Journal of Molecular Sciences, 2025;26(18):8881.
  • AIDS Weekly, October 20, 2025; p 50.